NAFLD-T2DM
Research type
Research Study
Full title
SCREENING OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND ADVANCED LIVER FIBROSIS IN PEOPLE WITH TYPE 2 DIABETES IN SECONDARY CARE DIABETES CLINICS: A PILOT STUDY
IRAS ID
326341
Contact name
Thinzar Min
Contact email
Sponsor organisation
Swansea Bay University Health Board
Duration of Study in the UK
1 years, 5 months, 31 days
Research summary
People with type 2 diabetes are at greater risk of several health concerns compared to people without type 2 diabetes, such as heart disease, stroke, eye problems, kidney disease and nerve damage. More recent studies show that many people with type 2 diabetes develop fatty liver disease, which increases the risk of liver irritation causing liver scarring and ultimately liver cirrhosis. Earlier stages of fatty liver disease are potentially reversible with lifestyle and diet changes, and more recent studies show some medications used for type 2 diabetes can reverse fatty liver disease. Currently there is no screening tests for this type of liver disease in people with type 2 diabetes, and patients are often diagnosed at later stages of cirrhosis which is currently incurable.
This study uses body measurements, additional blood tests and bedside scans of the liver to find out how many people living in Swansea Bay University Health Board catchment area with type 2 diabetes have this type of liver disease and whether your usual blood tests or any additional blood tests are useful to help diagnose patients with this condition. This might allow us to diagnose people with fatty liver disease more quickly, allowing these patients to be seen earlier by a liver specialist and treatment changed to prevent them developing liver cirrhosis in the future.REC name
Wales REC 3
REC reference
23/WA/0139
Date of REC Opinion
25 May 2023
REC opinion
Further Information Favourable Opinion